浙江拱东医疗器械股份有限公司关于“提质增效重回报”行动方案的公告

Core Viewpoint - The company has announced a "Quality Improvement and Efficiency Enhancement Action Plan" aimed at enhancing its core competitiveness and operational quality in the medical device industry, while also focusing on investor returns and protection of minority shareholders' rights [1][10]. Group 1: Business Focus and Operational Quality - The company is a leading player in the domestic medical device industry, with a strong focus on R&D, production, and sales of disposable medical consumables, laboratory consumables, and medical polymer products [1]. - In 2024, the company achieved a revenue of 1,115.21 million yuan, a year-on-year increase of 14.37%, and a net profit attributable to shareholders of 171.63 million yuan, up 57.28% from the previous year [2]. - Future strategies include enhancing R&D investment, focusing on high-end medical consumables and biopharmaceutical laboratory consumables, and optimizing production processes to improve capacity utilization and product quality [2]. Group 2: Governance and Compliance - The company has established a modern governance structure in compliance with relevant laws and regulations, ensuring clear division of responsibilities among shareholders, the board, and management [3]. - In 2024, the company revised several internal regulations to enhance governance and internal control systems, improving operational efficiency and compliance [4]. Group 3: Investor Relations and Information Disclosure - The company adheres to strict information disclosure standards, ensuring transparency and timely communication of strategic initiatives and operational results to investors [5]. - Future plans include enhancing the effectiveness of information disclosure, focusing on key investor concerns, and expanding communication channels with the capital market [6]. Group 4: Investor Returns - The company emphasizes reasonable returns for investors, with a cumulative cash dividend of 233.68 million yuan over the last three fiscal years, representing a cash dividend ratio of 115.53% [7]. - In 2024, the total amount for cash dividends and buybacks was 145.81 million yuan, accounting for 84.95% of the net profit attributable to shareholders, reflecting the company's commitment to shareholder returns [7]. Group 5: Management of Key Personnel - The company prioritizes the management of key personnel, including major shareholders and executives, through training and compliance awareness initiatives [8]. - Future efforts will focus on enhancing the performance evaluation and incentive mechanisms for key personnel, aligning their interests with the long-term goals of the company [8].